+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining Ivonescimab, a PD-1VEGF bispecific antibody, with docetaxel chemotherapy compared to standard treatment in patients with advanced non-small cell lung cancer NSCLC. This phase II randomized, open-label trial focuses on patients who have had long-term benefits from first-line immune checkpoint inhibitors but still show minimal residual disease as detected by circulating tumor DNA ctDNA. The study aims to develop precision-guided treatments to delay cancer progression by using molecular monitoring to guide therapy adjustments. Participants who test positive for ctDNA will receive an escalation treatment involving Ivonescimab administered intravenously every three weeks at 20 mgkg and docetaxel given intravenously every three weeks at 75 mgm, with possible dose adjustments for tolerance. Those continuing their original maintenance treatment, such as immunotherapy alone or combined with chemotherapy, form the standard treatment group. Treatment continues until clinical benefit ends, unacceptable toxicity occurs, 24 months of treatment are completed, or other protocol criteria are met. During the study, participants will undergo regular visits for imaging assessments, laboratory tests, and clinical evaluations to monitor disease status and treatment safety. Researchers will measure progression-free survival over three years as the primary outcome, along with overall survival, response rates, adverse events, quality of life, and ctDNA clearance. Safety monitoring continues up to 28 days after treatment ends, with follow-up extending to five years. The total participation duration varies based on treatment outcomes and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of hot spring balneotherapy on reducing central fatigue in adolescent rowers aged 12 to 16 years who are undergoing altitude training at about 1600 meters. The trial aims to compare natural recovery, warm water immersion, and hot spring immersion to see how each method influences brain-to-muscle activation, cognitive function, and exercise performance during this training. This randomized controlled trial uses a single-blind design for the immersion groups and is sponsored by Macao Polytechnic University. Participants are divided into three groups one with natural recovery involving passive rest and stretching without water immersion a second group receiving whole-body immersion in pure water at 38C for 20 minutes, three times per week and a third group undergoing hot spring water immersion with specific mineral content at the same temperature and frequency. All groups perform standardized rowing training for four weeks at altitude. Interventions happen on Tuesday, Thursday, and Saturday afternoons, with immersion sessions followed by rest. During the study, participants will be assessed at baseline, mid-intervention week 2, end of intervention week 4, and follow-up 1 to 2 weeks after altitude training ends. Researchers will measure central fatigue indicators such as voluntary activation and central activation ratio, cognitive tests including the Stroop test and Psychomotor Vigilance Test, cerebral blood flow, exercise capacity, and blood markers like lactate and white blood cell counts. The study monitors changes in these measures to understand how the different recovery methods affect fatigue and performance in adolescent athletes.

Age: 12Years - 16YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating how a 4-week altitude training program affects adolescent male rowers aged 12 to 19. The study focuses on changes in athletic performance, body composition, heart and lung function, and certain blood markers. Participants are grouped by biological maturation level measured by peak height velocity to see if maturity impacts how the training works. The program includes aerobic, anaerobic, and rowing-specific exercises conducted at high altitude over four weeks. Both groups, classified by maturity status Post-PHV and Mid-PHV, follow the same training plan. Measurements are taken before and immediately after the training period, including tests of rowing power, oxygen uptake, body fat, heart volume, lung capacity, and blood markers. Participants will have non-invasive tests of their athletic abilities, body composition, heart and lung function, plus venous blood samples to check blood markers. The study will monitor changes from before to after training and aims to optimize altitude training for youth rowers. Total participation covers the 4-week training and assessments done pre- and post-intervention.

Age: 12Years - 19YearsMALEPhase Not Applicable
1 location
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of two different altitude training strategies on physical performance and body adaptations in elite race walkers living at altitude. This randomized controlled trial compares alternating altitude training, which includes some sessions under simulated higher-altitude conditions, with fixed-altitude training, where all sessions occur at a regular altitude training base. The study focuses on assessing cardiovascular, pulmonary, and hematological changes to better understand how these approaches impact elite athletes. Participants will be randomly assigned to one of two groups. The alternating altitude training group will perform selected training sessions at simulated higher altitudes combined with regular altitude training, while the fixed-altitude group will complete all sessions at their usual altitude. The intervention lasts for 4 weeks, during which both groups follow the same prescribed training program adapted to their assigned altitude conditions. Throughout the 4-week intervention, participants will undergo various tests and measurements before and after training. These include body weight, body fat percentage, lung function tests like forced vital capacity and maximal voluntary ventilation, heart function assessments such as left ventricular volume and ejection fraction, and exercise capacity tests like maximal oxygen uptake and jump height. Blood samples will measure red blood cell counts, hemoglobin, hematocrit, and erythropoietin. These assessments help evaluate the physical and physiological impact of the two altitude training methods.

Age: 18Years - 26YearsMALEPhase Not Applicable
1 location
A

Actively Recruiting

Researchers are studying the prevalence of chronic obstructive pulmonary disease COPD among participants aged 40 years or older who have one of three types of cardiovascular diseases coronary heart disease, atrial fibrillation, or chronic heart failure. This multi-center, prospective, interventional study aims to understand how cardiopulmonary co-management affects the short-term health outcomes of participants with both cardiovascular disease and COPD. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease cohort. The study intervention includes guideline education and implementation at both the investigator and patient levels. Investigators receive education on COPD and cardiovascular disease about four weeks before enrolling participants. After enrollment, cardiologists and pulmonologists provide disease education every four weeks, along with collaborative treatment management for participants with both conditions. Participants are followed up every four weeks throughout the study. During the study, participants will undergo spirometry testing, complete questionnaires, and have various health measures recorded, including hospitalization rates and scores related to heart and lung function. Researchers will also monitor lung function tests, blood markers, and medication use at baseline and at weeks 4, 8, and 12. The primary outcome is the number and percentage of participants with COPD across the cardiovascular disease cohorts. The study includes short-term follow-up over 12 weeks to observe treatment and health changes.

Age: 40Years +All GendersPhase Not Applicable
85 locations
D

Actively Recruiting

Nasopharyngeal carcinoma NPC is a common cancer in regions like southern China, northern Africa, and Alaska, with a notably high rate in Guangdong Province. Early detection of NPC is important as early-stage patients tend to have better outcomes compared to those with advanced disease. Researchers are exploring the use of artificial intelligence to improve detection of early NPC through examination techniques using white light imaging WLI and narrow-band imaging NBI during nasoendoscopic procedures. This study aims to develop and validate a novel computer-aided diagnosis system to assist in identifying diverse nasopharyngeal lesions. The study involves the use of rigid nasal endoscopes inserted through the nasal passage to examine various areas of the nasopharynx under conventional white light and narrow-band imaging modes. Representative images are collected for analysis, and any lesions identified by either imaging method are biopsied. Participants are classified into groups based on pathological diagnosis by experienced pathologists, identifying either NPC or non-NPC conditions such as inflammatory hyperplasia or papilloma. Participants will undergo nasoendoscopic examination with image collection and biopsy as needed. The main outcome measure is the pathological diagnosis at baseline, with secondary outcomes including lesion range assessment. This observational study allows researchers to evaluate the effectiveness of the intelligent diagnostic system in detecting early NPC. The study is sponsored by the First Affiliated Hospital, Sun Yat-Sen University and is expected to continue until the end of 2026.

Age: 18Years +All Genders
3 locations